Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 82.89
+0.17 (0.21%)
Apr 1, 2026, 11:25 AM CET
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
€624,162
Profits / Employee
€104,388
Market Cap
99.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| emeis Société anonyme | 83,500 |
| Clariane SE | 70,685 |
| Eurofins Scientific SE | 65,694 |
| Ramsay Générale de Santé | 40,000 |
| bioMérieux | 15,226 |
| Sartorius Stedim Biotech | 10,265 |
| Virbac | 6,365 |
Sanofi News
- 1 day ago - Sanofi Receives EU Conditional Marketing Authorization For Rezurock In Chronic GVHD - Nasdaq
- 1 day ago - Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock - Nasdaq
- 1 day ago - Sanofi: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease - Finanz Nachrichten
- 1 day ago - Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease - GlobeNewsWire
- 1 day ago - Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease - Benzinga
- 3 days ago - Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis - Nasdaq
- 3 days ago - Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session - Finanz Nachrichten
- 3 days ago - Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session - GlobeNewsWire